Evolution of extravascular implantable defibrillator technologies

Anna Pfenniger; Bradley P. Knight

doi:10.1016/j.pcad.2019.04.003

Evolution of extravascular implantable defibrillator technologies

Anna Pfenniger, Bradley P. Knight^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.

Original language	English (US)
Pages (from-to)	249-255
Number of pages	7
Journal	Progress in Cardiovascular Diseases
Volume	62
Issue number	3
DOIs	https://doi.org/10.1016/j.pcad.2019.04.003
State	Published - May 1 2019

Keywords

Modular cardiac rhythm management system
S-ICD
Subcutaneous implantable cardioverter-defibrillator
Substernal lead
Ventricular arrhythmias

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.pcad.2019.04.003

Cite this

@article{52fccdab1b3e440aa80a73ac1a877712,

title = "Evolution of extravascular implantable defibrillator technologies",

abstract = "The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.",

keywords = "Modular cardiac rhythm management system, S-ICD, Subcutaneous implantable cardioverter-defibrillator, Substernal lead, Ventricular arrhythmias",

author = "Anna Pfenniger and Knight, {Bradley P.}",

year = "2019",

month = may,

day = "1",

doi = "10.1016/j.pcad.2019.04.003",

language = "English (US)",

volume = "62",

pages = "249--255",

journal = "Progress in Cardiovascular Diseases",

issn = "0033-0620",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Evolution of extravascular implantable defibrillator technologies

AU - Pfenniger, Anna

AU - Knight, Bradley P.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.

AB - The implantable cardioverter-defibrillator (ICD) has been successfully treating patients with lethal ventricular arrhythmias for decades. The main acute and chronic complications of this therapy modality are related to the use of a transvenous lead. An entirely extravascular ICD concept was developed over the last 20 years, with emergence of the subcutaneous ICD (S-ICD). This device was approved for clinical use seven years ago, and accumulating real-life experience confirms its safety and efficacy. The main limitations related to this system include the lack of pacing capabilities for bradycardia, tachycardia or resynchronization therapy, a large size, and relatively high energy requirements for effective defibrillation. This review article summarizes current knowledge and potential future developments of the extravascular ICD technologies.

KW - Modular cardiac rhythm management system

KW - S-ICD

KW - Subcutaneous implantable cardioverter-defibrillator

KW - Substernal lead

KW - Ventricular arrhythmias

UR - http://www.scopus.com/inward/record.url?scp=85064734221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064734221&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2019.04.003

DO - 10.1016/j.pcad.2019.04.003

M3 - Review article

C2 - 31004606

AN - SCOPUS:85064734221

SN - 0033-0620

VL - 62

SP - 249

EP - 255

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

IS - 3

ER -

Evolution of extravascular implantable defibrillator technologies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this